Journal ArticleJ Surg Res · January 13, 2025
INTRODUCTION: Optimal treatment of stage I-III breast cancer requires multimodal therapies. Patients can receive these therapies at one or multiple facilities. Herein, we evaluated the association of receiving treatment at more than one facility and distan ...
Full textLink to itemCite
Journal ArticleAnn Surg Oncol · December 2024
BACKGROUND: Older breast cancer patients represent a heterogeneous population. Studies demonstrate that sentinel lymph node biopsy (SLNB) omission may be appropriate in some clinical scenarios, yet patients with triple-negative breast cancer (TNBC) are oft ...
Full textLink to itemCite
ConferenceAnn Surg Oncol · November 2024
BACKGROUND: Patients with inflammatory breast cancer (IBC) have worse survival compared with stage III non-IBC matched cohorts; however, the prognostic significance of achieving pathologic complete response (pCR) in the setting of IBC is not well described ...
Full textLink to itemCite
Journal ArticleJ Surg Res · October 2024
INTRODUCTION: Stage III breast cancer is defined as locally advanced breast cancer and is treated with curative intent. Historically, overall survival (OS) did not differ based on treatment sequence (neoadjuvant chemotherapy [NAC] followed by surgery versu ...
Full textLink to itemCite
Journal ArticleAm J Surg · July 2024
BACKGROUND: The predictive and prognostic value of the recurrence score (RS) has emphasized the importance of tumor biology and has reduced the prognostic implications of limited nodal burden in post-menopausal women with HR+/HER2-invasive breast cancer (I ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · May 10, 2024
PURPOSE: Black women have higher rates of death from triple-negative breast cancer (TNBC) than White women. We hypothesized that pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and overall survival (OS) may vary by race/ethnicity in pa ...
Full textLink to itemCite
Journal ArticleJ Surg Res · April 2024
INTRODUCTION: With the increasing utilization of genomic assays, such as the Oncotype DX recurrence score (RS), the relevance of anatomic staging has been questioned for select older patients with breast cancer. We sought to evaluate differences in chemoth ...
Full textLink to itemCite
Journal ArticleAnn Surg Oncol · October 2023
BACKGROUND: Axillary surgery after neoadjuvant chemotherapy (NAC) is becoming less extensive. We evaluated the evolution of axillary surgery after NAC on the multi-institutional I-SPY2 prospective trial. METHODS: We examined annual rates of sentinel lymph ...
Full textLink to itemCite
Journal ArticleAnn Surg · September 1, 2023
Neoadjuvant chemotherapy (NAC) increases rates of successful breast-conserving surgery (BCS) in patients with breast cancer. However, some studies suggest that BCS after NAC may confer an increased risk of locoregional recurrence (LRR). We assessed LRR rat ...
Full textLink to itemCite
ConferenceCancer Research · March 1, 2023
AbstractIntroduction: Despite the recent overall improvement in survival for patients with breast cancer, racial disparities in outcomes persist. While studies have demonstrated that socioeconomic factors an ...
Full textCite
Journal ArticleAm Surg · August 1, 2018
We investigated the patterns of injury associated with major midface trauma. Our hypothesis is that midface injuries are associated with a decrease in certain traumatic brain injuries as well as major torso injuries. The registry of our Level I trauma cent ...
Link to itemCite